FDA — authorised 17 October 1974
- Application: ANDA080767
- Marketing authorisation holder: IMPAX LABS
- Status: supplemented
🇺🇸 Placebo for "Deficiency of Qi and Yin" in United States
FDA authorised Placebo for "Deficiency of Qi and Yin" on 17 October 1974
Marketing authorisations
FDA — authorised 28 August 1981
- Application: ANDA086173
- Marketing authorisation holder: FOSUN PHARMA
- Status: supplemented
FDA — authorised 17 September 2010
- Application: ANDA079025
- Marketing authorisation holder: CHARTWELL RX
- Status: approved
FDA — authorised 21 December 2011
- Application: ANDA090653
- Marketing authorisation holder: HOSPIRA INC
- Status: approved
FDA — authorised 26 June 2012
- Application: ANDA090979
- Marketing authorisation holder: PADAGIS ISRAEL
- Status: approved
Frequently asked questions
Is Placebo for "Deficiency of Qi and Yin" approved in United States?
Yes. FDA authorised it on 17 October 1974; FDA authorised it on 28 August 1981; FDA authorised it on 17 September 2010.
Who is the marketing authorisation holder for Placebo for "Deficiency of Qi and Yin" in United States?
IMPAX LABS holds the US marketing authorisation.